Osteoarthritis Clinical Trials

Find Osteoarthritis Clinical Trials Near You

Comparison of Three Variants of PENG Block Using 20 mL of 0.2% Ropivacaine With Different Combinations of Dexamethasone and Perineural Dexmedetomidine in Patients Aged 65 Years and Older Undergoing Hip Surgery: A Randomized Controlled Trial.

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study will compare three different versions of the Pericapsular Nerve Group (PENG) block in adults aged 65 years and older who are undergoing surgery for hip conditions. The PENG block is a regional anesthesia technique that can reduce pain after surgery and decrease the need for strong opioid pain medications. All patients in the study will receive the PENG block with 20 mL of 0.2% ropivacaine, but they will be divided into three groups based on the additional medications used: Group 1: PENG block with ropivacaine plus 4 mg of dexamethasone given intravenously. Group 2: PENG block with ropivacaine plus 25 micrograms of dexmedetomidine given near the nerves and 4 mg of dexamethasone given intravenously. Group 3: PENG block with ropivacaine plus 25 micrograms of dexmedetomidine and 4 mg of dexamethasone given near the nerves. Both dexmedetomidine and dexamethasone are medications that may improve the strength and duration of nerve blocks. The main goal of this study is to determine which combination provides the best pain control after hip surgery, reduces the need for opioid medications, and improves patient comfort and recovery. We also aim to evaluate the safety and side-effects of each technique. We hypothesize that adding both dexmedetomidine and dexamethasone near the nerves will provide the longest and most effective pain relief when compared to intravenous administration alone. This trial may help identify the most effective PENG block formula for older adults undergoing hip surgery and could improve pain management, decrease complications related to opioids, and support faster recovery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Maximum Age: 100
Healthy Volunteers: f
View:

• Age 65 years or older

• Scheduled for elective or emergency hip surgery (e.g., hip fracture fixation or hip arthroplasty)

• ASA physical status I-III

• Ability to communicate pain intensity using the NRS scale

• Written informed consent obtained from the patient or legal representative

• Planned use of PENG block as part of multimodal perioperative analgesia

Locations
Other Locations
Poland
Poznan University of Medical Sciences
RECRUITING
Poznan
Contact Information
Primary
Malgorzata Reysner, MD PhD
mreysner@ump.edu.pl
+48 61 873 83 03
Backup
Mslgorzata Reysner, MD PhD
mreysner@ump.edu.pl
+48 61 873 83 03
Time Frame
Start Date: 2026-02-13
Estimated Completion Date: 2027-01-31
Participants
Target number of participants: 120
Treatments
Active_comparator: PENG Block With Intravenous Dexamethasone
Participants will receive a Pericapsular Nerve Group (PENG) block using 20 mL of 0.2% ropivacaine. As part of the study medications, they will receive 4 mg of dexamethasone intravenously and perineural normal saline as placebo, so that the number and volume of injections are identical across all groups.
Active_comparator: PENG Block With Perineural Dexmedetomidine and Intravenous Dexamethasone
Participants will receive a PENG block using 20 mL of 0.2% ropivacaine combined with 25 µg of dexmedetomidine administered perineurally. In addition, they will receive 4 mg of dexamethasone intravenously. Perineural normal saline may be added to match the total volume of perineural injectate across groups.
Experimental: PENG Block With Perineural Dexmedetomidine and Perineural Dexamethasone
Participants will receive a PENG block using 20 mL of 0.2% ropivacaine combined with 25 µg of dexmedetomidine and 4 mg of dexamethasone administered perineurally. Intravenously they will receive normal saline as placebo instead of dexamethasone in order to maintain blinding.
Related Therapeutic Areas
Sponsors
Leads: Poznan University of Medical Sciences

This content was sourced from clinicaltrials.gov

Similar Clinical Trials